CENTER FOR DRUG EVALUATION AND RESEARCH

APPLICATION NUMBER:

74517

CHEMISTRY REVIEW(S)

1. CHEMISTRY REVIEW NO #4

2. ANDA 74-517

3. NAME AND ADDRESS OF APPLICANT
Eon Labs Manufacturing, Inc.
Attention : Edward Shinal, Ph.D.
227-15 North Conduit Avenue
Laurelton, New York 11413

4. LEGAL BASIS FOR SUBMISSION
The listed drug, which is the basis for this ANDA is Wytensin®, brand of guanabenz acetate 4 mg and 8 mg tablets, manufactured by Wyeth-Ayerst Laboratories, Inc. There are no effective patents and no exclusivity for NDA 18-587.

5. SUPPLEMENT(s)
N/A

6. PROPRIETARY NAME
N/A

7. NONPROPRIETARY NAME
Guanabenz Acetate Tablets, USP

8. SUPPLEMENT(s) PROVIDE(s) FOR:
N/A

9. AMENDMENTS AND OTHER DATES:
Firm:
June 30, 1994: Original submission
May 1, 1995: Amendment
November 19, 1997: Amendment
June 24, 1998: Facsimile amendment

FDA:
September 1, 1994: Acknowledgement Letter
December 21, 1994: Deficiency letter#1
April 24, 1995: Bio. deficiency letter
November 14, 1995: Bio. deficiency letter
December 15,1995: Chemistry deficiency#2
June 17, 1998: Facsimile deficiency letter

10. PHARMACOLOGICAL CATEGORY
Antihypertension

11. Rx or OTC
Rx

12. RELATED IND/NDA/DMF(s)
DMF#
DMF#
DMF#
DMF#
DMF#
DMF#
DMF#

DMF#
DMF#
DMF#
DMF#
DMF#
DMF#

13. DOSAGE FORM
Tablets

14. POTENCY
4 mg and 8 mg

15. CHEMICAL NAME AND STRUCTURE
Guanabenz Acetate USP

$C_8H_8Cl_2N_4.C_2H_4O_2$; M.W. = 291.14



[(2,6-Dichlorobenzylidene)amino] guanidine monoacetate.
CAS [23256-50-0]

16. RECORDS AND REPORTS
On July 19, 1994 Bill Russell sent a memo regarding packaging of exhibit batches to Director, Division of Chemistry I. Based on the office policy of requiring complete packaging of the exhibit batches of oral solid dosage forms, they requested a determination of acceptability for filing of the application in regards to the packaging requirement. The Director of Division I determined that the packaging section of this application was acceptable.

Phone conversation between FDA and Eon Lab on 2-24-95. Called to clarify item 5b of December 21, 1994 deficiency letter. Dr Simmons and Dr Basaran discussed impurity measurement and appropriate levels as expressed in terms of USP requirements and total related compounds. No specific specifications were determined, however, we requested and the firm agreed to address this deficiency by:

1. Offering a limit specification for the z-isomer, based on data.

2. Offer a limit specification for total related compounds.

3. Submit the raw data for our review in determining the appropriateness of the offered specifications.

17. COMMENTS
The following deficiencies are found:
None

18. CONCLUSIONS AND RECOMMENDATIONS
The application can be approved. A approval letter will be issued.

19. REVIEWER: Sema Basaran, Ph.D. DATE COMPLETED: 6-30-98/8-28-98